share_log

Shanghai No.1 PharmacyLtd's (SHSE:600833) Three-year Earnings Growth Trails the 22% YoY Shareholder Returns

Shanghai No.1 PharmacyLtd's (SHSE:600833) Three-year Earnings Growth Trails the 22% YoY Shareholder Returns

上海第一药业有限公司(SHSE:600833)的三年盈利增速低于22%的股东回报率
Simply Wall St ·  11/08 06:26

By buying an index fund, you can roughly match the market return with ease. But if you choose individual stocks with prowess, you can make superior returns. For example, the Shanghai No.1 Pharmacy Co.,Ltd. (SHSE:600833) share price is up 76% in the last three years, clearly besting the market decline of around 15% (not including dividends). However, more recent returns haven't been as impressive as that, with the stock returning just 26% in the last year, including dividends.

通过购买指数基金,您可以轻松地大致匹配市场回报。但如果您选择具有实力的个别股票,您可以获得更高的回报。例如,上海第一医药股份有限公司(SHSE:600833)的股价在过去三年中上涨了76%,明显超过了市场大约15%的下跌(不包括分红)。然而,最近的回报并不像那样令人印象深刻,该股票在过去一年中仅回报26%,包括分红。

Since it's been a strong week for Shanghai No.1 PharmacyLtd shareholders, let's have a look at trend of the longer term fundamentals.

由于上海第一医药股份有限公司股东上周表现强劲,让我们来看一下更长期基本面的趋势。

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

用本杰明·格雷厄姆的话来说:“短期市场是一台投票机,但长期市场是一台称重机”。检查市场情绪如何随时间推移变化的一种方式是查看公司股价和每股收益(EPS)之间的相互作用。

During three years of share price growth, Shanghai No.1 PharmacyLtd achieved compound earnings per share growth of 56% per year. This EPS growth is higher than the 21% average annual increase in the share price. Therefore, it seems the market has moderated its expectations for growth, somewhat.

在股价增长的三年期间,上海第一医药股份有限公司实现了每股收益的复合年增长率为56%。这种每股收益增长高于股价平均年增长率21%。因此,市场似乎已经适度降低了对增长的期望。

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

您可以在下面的图片中查看每股收益如何随时间变化(单击图表以查看确切的价值)。

big
SHSE:600833 Earnings Per Share Growth November 7th 2024
SHSE:600833每股收益增长2024年11月7日

Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.

在购买或出售股票之前,我们始终建议对历史增长趋势进行仔细研究,可以在这里找到相关信息。

What About Dividends?

关于分红派息的问题

It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, Shanghai No.1 PharmacyLtd's TSR for the last 3 years was 82%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!

对于任何一支股票,考虑总股东回报以及股价回报是很重要的。TSR包括任何拆股或折价增资的价值,以及基于股息被再投资的假设。可以说TSR更全面地反映了支付股息的股票。上海第一医药过去3年的TSR达到了82%,超过了前文提到的股价回报,这在很大程度上是由于其股息支付!

A Different Perspective

另一种看法

It's good to see that Shanghai No.1 PharmacyLtd has rewarded shareholders with a total shareholder return of 26% in the last twelve months. And that does include the dividend. That gain is better than the annual TSR over five years, which is 11%. Therefore it seems like sentiment around the company has been positive lately. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. It's always interesting to track share price performance over the longer term. But to understand Shanghai No.1 PharmacyLtd better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Shanghai No.1 PharmacyLtd (at least 1 which is concerning) , and understanding them should be part of your investment process.

很高兴看到上海第一医药在过去12个月内以26%的总股东回报来奖励股东,其中包括股息。这一收益好于过去5年的年度TSR,为11%。因此,最近公司周围的情绪似乎是积极的。鉴于股价势头仍然强劲,值得更仔细地观察该股,以免错失机会。长期跟踪股价表现总是有趣的。但要更好地了解上海第一医药,我们需要考虑许多其他因素,例如,永远存在的投资风险。我们确定了上海第一医药的2个警示信号(至少有1个令人担忧),了解这些应该是你投资过程的一部分。

If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying.

如果您和我一样,那么您一定不想错过这份免费的被内部人员买入的低估小盘股清单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文中引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发